| Name | Title | Contact Details |
|---|
Optimal Radiology is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Originally organized in the late 1880’s, the Gaston County Family YMCA has upheld the remaining constant of the Christian Mission of the YMCA and the outstanding leadership provided by countless volunteers and staff. Together the YMCA of Gaston County ...
CareBridge offers a patented EVV solution for personal care services, home health services, and health plan care managers. Originally launched in 2009, CareBridge has spent more than a decade refining our technology through multiple statewide rollouts.
The Wound Pros, LLC is a physician-owned Medicare Part B supplier of the industry’s most advanced wound care dressings. As a bonus, Wound Pros offers excellent clinical expertise which gives our patients the best opportunity to heal efficiently. Our vision is to change the way the world treats and manages non-healing wounds. Chronic non-healing wounds can compromise the quality of life for those living in long-term care facilities. The longer a wound remains open or unhealed, the greater the chance of unwanted complications such as infection, hospitalisation, and even amputation. At The Wound Pros, we are dedicated to meeting this challenge head-on with our "Hi-Tech Hi-Touch Approach” to wound care management. Our vision is to change the way the world treats and manages chronic non-healing wounds with better data, better decision making and better documentation.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.